Abstract
Teclistamab (TECVAYLI (R)), a bispecific antibody that targets CD3 and B cell maturation antigen (BCMA), is being developed by Janssen Research and De......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
